Illinois is currently home to 2639 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT04893109
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Cardiogenic Shock Working Group Registry
NCT04682483
Recruiting
The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Cardiogenic Shock
Register for Updates
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647
Recruiting
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Gender:
ALL
Ages:
Between 6 years and 100 years
Trial Updated:
06/03/2025
Locations: Willow Rheumatology Wellness, Willowbrook, Illinois
Conditions: Autoimmunity, Inflammation
Register for Updates
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202
Recruiting
This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/03/2025
Locations: Illinois CancerCare-Bloomington, Bloomington, Illinois
Conditions: Colorectal Cancer, Sarcopenia
Register for Updates
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
NCT03901924
Recruiting
The objective of the study is to determine how controlled mode ventilation and support mode ventilation impact ventilator-free days and diaphragmatic atrophy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Mechanical Ventilation Complication
Register for Updates
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
NCT03339128
Recruiting
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/03/2025
Locations: Advocate Children's Hospital-Park Ridge /ID# 235388, Park Ridge, Illinois
Conditions: Irritable Bowel Syndrome
Register for Updates
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
NCT03251118
Recruiting
TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/03/2025
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis
Register for Updates
Early PKD Observational Cohort Study
NCT02936791
Recruiting
This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being develop... Read More
Gender:
ALL
Ages:
Between 4 years and 35 years
Trial Updated:
06/03/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Polycystic Kidney Disease
Register for Updates
Effect of ANNE One-Wellue Device Array Use on Staff Bedside Vital Sign Measurement Activity
NCT06995742
Recruiting
Randomized controlled trial of a time motion study of time spent obtaining and charting vital signs for inpatients, comparing use of a wireless Bluetooth vital sign array as intervention versus routine vital sign obtainment activity on a general medical floor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Feinberg 16 West, Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Vital Sign Evaluation, Vital Sign Monitoring, Sleep Quality, Provider Behavior, Patient Satisfaction
Register for Updates
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NCT06941844
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/02/2025
Locations: Uptown Research, Chicago, Illinois
Conditions: Major Depressive Disorder
Register for Updates
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
NCT06773910
Recruiting
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Illinois Cancer Specialists, Arlington Heights, Illinois
Conditions: Limited Stage Small Cell Lung Cancer
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
NCT06741228
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/02/2025
Locations: Uptown Research Institute, Chicago, Illinois
Conditions: Generalized Anxiety Disorder
Register for Updates